Medpace Holdings, Inc. (MEDP) Shares Outstanding: 0.03
Is Medpace Holdings, Inc.’s shares outstanding high or low?
Medpace Holdings, Inc.'s shares outstanding of 0.03 is 11% below its 5-year average of 0.03, near the low end of its 5-year range (0.03–0.04).
3.53% below its 12-month average of 0.03.
MEDP Shares Outstanding Chart
MEDP Average Shares Outstanding Chart
MEDP Current vs Average Shares Outstanding Chart
MEDP Shares Outstanding Metrics
SHARES OUTSTANDING
0.03
SHARES OUTSTANDING AVG TTM
0.03
SHARES OUTSTANDING AVG 3Y
0.03
SHARES OUTSTANDING AVG 5Y
0.03
SHARES OUTSTANDING AVG 10Y
0.03
SHARES OUTSTANDING AVG 15Y
N/A
SHARES OUTSTANDING AVG 20Y
N/A
CURRENT VS TTM AVG
-3.53%
CURRENT VS 3Y AVG
-6.13%
CURRENT VS 5Y AVG
-10.97%
CURRENT VS 10Y AVG
-16.55%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Share Structure
Shares Outstanding
28.85M
Float Shares
N/A
Stock Price
$461.60
Market Cap
$13.2B
Annual Shares Outstanding History
| Year | Weighted Average Shares | YoY Change |
|---|---|---|
| 2025 | 28.85M | -6.82% |
| 2024 | 30.96M | +0.76% |
| 2023 | 30.72M | -5.14% |
| 2022 | 32.39M | -9.69% |
| 2021 | 35.86M | +0.64% |
| 2020 | 35.63M | -0.69% |
| 2019 | 35.88M | +0.94% |
| 2018 | 35.55M | -8.98% |
| 2017 | 39.06M | +9.43% |
| 2016 | 35.69M | -9.94% |
| 2015 | 39.63M | +34.65% |
| 2014 | 29.43M | -23.24% |
| 2013 | 38.35M | - |
Relationship: Market Cap = Shares Outstanding × Stock Price
Key concepts:
- Float shares: Shares available for public trading
- Dilution: When new shares are issued, existing shareholders own less
- Buybacks: Reduce share count, increasing EPS and ownership stake
- Stock splits: Increase share count but don't change market cap
Medpace Holdings, Inc. Shares Outstanding Formula & Definition
Shares Outstanding represents the total number of shares issued by a company that are held by all shareholders. Changes in share count affect EPS and ownership dilution.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medpace Holdings, Inc. Shares Outstanding FAQ
- What is the shares outstanding for Medpace Holdings, Inc. (MEDP)?
- The shares outstanding for MEDP stock is 0.03.
- Is Medpace Holdings, Inc.'s shares outstanding high or low?
- Medpace Holdings, Inc.'s shares outstanding of 0.03 is 11% below its 5-year average of 0.03, near the low end of its 5-year range (0.03–0.04).
- What is the TTM average shares outstanding for Medpace Holdings, Inc. (MEDP)?
- The TTM average shares outstanding for MEDP stock is 0.03.
- What is the 3Y average shares outstanding for Medpace Holdings, Inc. (MEDP)?
- The 3Y average shares outstanding for MEDP stock is 0.03.
- What is the 5Y average shares outstanding for Medpace Holdings, Inc. (MEDP)?
- The 5Y average shares outstanding for MEDP stock is 0.03.
- What is the 10Y average shares outstanding for Medpace Holdings, Inc. (MEDP)?
- The 10Y average shares outstanding for MEDP stock is 0.03.
Medpace Holdings, Inc. Shares Outstanding History
| DATE | SHARES OUTSTANDING |
|---|---|
| 2025-12-31 | 0.03 |
| 2024-12-31 | 0.03 |
| 2023-12-31 | 0.03 |
| 2022-12-31 | 0.03 |
| 2021-12-31 | 0.04 |
| 2020-12-31 | 0.04 |
| 2019-12-31 | 0.04 |
| 2018-12-31 | 0.04 |
| 2017-12-31 | 0.04 |
| 2016-12-31 | 0.04 |
| 2015-12-31 | 0.04 |
| 2014-12-31 | 0.03 |
| 2013-12-31 | 0.04 |
Related Metrics
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle